ARTICLE | Clinical News

Zadaxin thymosin alpha 1 data

November 21, 1994 8:00 AM UTC

SCLN (San Mateo, Calif.) announced data from an on-going Phase III trial in which patients received Zadaxin and alpha-2B interferon, reporting statistically significant, complete normalization of the liver enzyme alanine amino- transferase (ALT), compared to patients receiving placebo or interferon alone.

As presented at the meeting of the American Association for the Study of Liver Diseases in Chicago, almost 50 percent of the 65 patients had complete normalization of ALT. Less than 20 percent of the group receiving interferon alone had normal ALT levels. ...